[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2013CN02996A - - Google Patents

Download PDF

Info

Publication number
IN2013CN02996A
IN2013CN02996A IN2996CHN2013A IN2013CN02996A IN 2013CN02996 A IN2013CN02996 A IN 2013CN02996A IN 2996CHN2013 A IN2996CHN2013 A IN 2996CHN2013A IN 2013CN02996 A IN2013CN02996 A IN 2013CN02996A
Authority
IN
India
Prior art keywords
desmosterol
disease
alzheimer
cognitive impairment
mild cognitive
Prior art date
Application number
Inventor
Yoshiaki Sato
Ken Aoshima
Francois Bernie
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IN2013CN02996A publication Critical patent/IN2013CN02996A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/203332—Hydroxyl containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Desmosterol alone the combination of desmosterol and amyloid beta the combination of desmosterol and gelsolin and the combination of desmosterol amyloid beta and gelsolin can be used as in blood biomarkers for Alzheimer s disease or mild cognitive impairment. Provided are: a method using these biomarkers for evaluating the effect of candidate substances for treatment agents for Alzheimer s disease or mild cognitive impairment; a method for assisting in the diagnosis of Alzheimer s disease or mild cognitive impairment; and a method for diagnosing Alzheimer s disease or mild cognitive impairment.
IN2996CHN2013 2010-10-20 2011-06-23 IN2013CN02996A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010235203 2010-10-20
US201061424885P 2010-12-20 2010-12-20
JP2010282938 2010-12-20
PCT/JP2011/064487 WO2012053255A1 (en) 2010-10-20 2011-06-23 Biomarker for alzheimer's disease or mild cognitive impairment

Publications (1)

Publication Number Publication Date
IN2013CN02996A true IN2013CN02996A (en) 2015-08-14

Family

ID=45974981

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2996CHN2013 IN2013CN02996A (en) 2010-10-20 2011-06-23

Country Status (10)

Country Link
US (1) US9581604B2 (en)
EP (1) EP2631646B1 (en)
JP (1) JP5695075B2 (en)
AU (1) AU2011319319B2 (en)
BR (1) BR112013009592A2 (en)
CA (1) CA2814385C (en)
IN (1) IN2013CN02996A (en)
NZ (1) NZ609324A (en)
RU (1) RU2563987C2 (en)
WO (1) WO2012053255A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212084D0 (en) * 2012-07-06 2012-08-22 Randox Lab Ltd Tropomyosin isoforms related to alzheimers disease and mild cognitive impairment
JP6569919B2 (en) * 2015-03-06 2019-09-04 国立大学法人 新潟大学 Biomarkers for dementia with Lewy bodies
ES2657414T3 (en) * 2015-11-20 2018-03-05 Geroa Diagnostics, S.L Use of lactoferrin in the diagnosis or prognosis of Alzheimer's disease
CN114410774A (en) * 2022-02-17 2022-04-29 杭州怡健医疗科技有限公司 Risk assessment method applied to Alzheimer's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226401A1 (en) * 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
JPWO2007097461A1 (en) 2006-02-27 2009-07-16 国立大学法人 熊本大学 Antibody for hepatitis C treatment
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
RU2356058C2 (en) * 2006-11-27 2009-05-20 Александр Васильевич Мальцев Method of amyloidosis diagnostics in patients with alzheimerts disease and set of means for its realisation

Also Published As

Publication number Publication date
US9581604B2 (en) 2017-02-28
RU2563987C2 (en) 2015-09-27
EP2631646A4 (en) 2014-05-07
JPWO2012053255A1 (en) 2014-02-24
CA2814385C (en) 2017-10-24
US20130266589A1 (en) 2013-10-10
BR112013009592A2 (en) 2016-07-12
AU2011319319A1 (en) 2013-05-02
WO2012053255A1 (en) 2012-04-26
JP5695075B2 (en) 2015-04-01
EP2631646A1 (en) 2013-08-28
NZ609324A (en) 2014-09-26
EP2631646B1 (en) 2016-10-19
AU2011319319B2 (en) 2015-07-30
RU2013122853A (en) 2014-11-27
CA2814385A1 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
UA101167C2 (en) Pharmaceutical composition useful for the treatment of ocular disease
BR112013022493A2 (en) equipment and method for examining, diagnosing or assisting in the diagnosis and treatment of functional vision problems
EA201400491A1 (en) ACCOMPANYING DIAGNOSTICS FOR THERAPY WITH ANTIHIALURON AGENT AND METHODS
WO2010091049A3 (en) Diagnosis and treatment of cancer
SG179095A1 (en) Novel assay for the detection of amyloid beta peptides
IL222252A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
BR112014018592A2 (en) composition and method for the diagnosis and treatment of diseases associated with neuronal degeneration
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
HK1145087A1 (en) Diagnostic agent
EP2240077A4 (en) System and method of cosmetic analysis and treatment diagnosis
EP2323680A4 (en) Proteins for use in diagnosing and treating infection and disease
EP2509488A4 (en) Methods and arrangements for analysis, diagnosis, and treatment monitoring of vocal folds by optical coherence tomography
WO2016040891A3 (en) In vitro compositions comprising human sample and amyloid targeting agent
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
BR112013016107A2 (en) dimeric molecule, cancer treatment method, pharmaceutical composition and kit for the diagnosis of an upar-mediated pathology or tumor
EP2260107A4 (en) Assays for diagnosing and evaluating treatment options for pompe disease
WO2013164763A3 (en) A biological complex specific for alzheimer's disease detection in vitro and use thereof
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
BR112014007007A2 (en) early differentiation method, fibrillation diagnostic method, cardiac troponin use, differentiation device and diagnostic device
IN2013CN02996A (en)
IT1400684B1 (en) IMAGING METHOD AND DEVICE FOR THE MONITORING OF AN EXAMINED BODY.
WO2012004276A3 (en) Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
WO2013064702A3 (en) Probes for diagnosis and monitoring of neurodegenerative disease
BR112012009859A2 (en) diagnostic composition, diagnostic method, and in vivo imaging detection method
DK2248825T3 (en) Antigen-binding fragment of an antibody for use in the treatment and diagnosis of ocular diseases